[{"data":1,"prerenderedAt":261},["ShallowReactive",2],{"story-31528-cn":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":47,"questions":48,"relatedArticles":61,"body_color":259,"card_color":260},"31528",null,"FDA Regulatory Pathway Signals Biotech Compliance Opportunities","- Breakthrough Immunotherapy Reveals Regulatory Navigation Strategies for Healthcare Sellers",[],[10,11,12,13,14,15,16,17,18,19,20,21,12,22,23,24,25,26,27,28,29,30,31,32,33,27,34,35,36,35,37,38,39,40,41,42,43,44,45,46],"https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2170812299-750x406.jpg","https://static.zawya.com/view/acePublic/alias/contentid/OGE2NDM0OTItNTc4Mi00/1/1264092805.webp?f=3%3A2&q=0.75&w=3840","https://news.stocktwits-cdn.com/large_immunitybio_stock_jpg_9eab8bde17.webp","https://www.sadanews.ps/cached_uploads/resize/960/831/2025/12/17/79af5b4d4dcc19b9b62e4f114e1c15a4-1765980339.webp","https://static.asianetnews.com/images/w-1280,h-720,format-webp,imgid-external,imgname-image-f079caf7-46d0-4ad6-bdcd-0bbb788efa98.webp","https://s.yimg.com/ny/api/res/1.2/bIQhTzG0fWfhvKqKiovlLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xMDcy/https://media.zenfs.com/en/motleyfool.com/b2266bf4e5454ef1a196b91a1f82ea1a","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F851657%2Fgettyimages-1205459956.jpg&w=1200&op=resize","https://sherwoodnews.imgix.net/mwphzyq69oso/en-US/assets/files/158091560_various-pills-on-checkerboard.jpg?w=1600&auto=compress%2Cformat&cs=srgb","https://www.oncologypipeline.com/apexonco/sites/default/files/styles/large/public/articles/FDA_3.jpg","https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c938edb4afe94504a53c6475401ca86ae0b23b8a-3840x2160.jpg","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://cdn.thepharmaletter.com/files/2024/04/c778fb50-0154-11ef-a588-e798d47e404e-immunitybio_large.jpg","https://imonkey-blog.imgix.net/blog/wp-content/uploads/2026/01/17030611/Screenshot-2026-01-17-at-4.05.55%E2%80%AFPM.png","https://oncodaily.com/pub/uploads/2026/01/Saudi-FDA-Approves-Anktiva.webp","https://ts2.tech/wp-content/uploads/2026/01/why-immunitybio-stock-jumped-nearly-40-anktiva-sales-surge-and-a-fresh-trial-timeline-featured.jpg","https://cdn.sanity.io/images/0vv8moc6/onclive/8f52a6976e914d5bcb8f5f2ff125ca86a0b17fce-1200x1650.jpg?w=1200&max-h=1650&fit=crop&auto=format","https://static.asianetnews.com/images/w-1280,h-720,format-webp,imgid-external,imgname-image-2a201ff4-81b0-4f3a-9181-37717ebf6101.webp","https://images.barrons.com/im-95345013?width=700&height=466","https://s.yimg.com/ny/api/res/1.2/t5SDWaABlzTxKWGUBP0C5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xMDcy/https://media.zenfs.com/en/motleyfool.com/ece2644f62c999828edb4a744e8a56b7","https://blog.tipranks.com/wp-content/uploads/2026/01/shutterstock_264590948-750x406.jpg","https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F23fc1b822f8eafa9d627ca7fbac8d5b39aebf467-1401x1251.png%3Fw%3D1401%26h%3D1251&w=1200&op=resize","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1249101909/image_1249101909.jpg?io=getty-c-w1536","https://s.yimg.com/ny/api/res/1.2/bW5oSBIPPi2R14QCqRa78g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNw--/https://media.zenfs.com/en/insidermonkey.com/7388cae081bf4d43e11b4ffb83909080","https://s.yimg.com/ny/api/res/1.2/r5oZi9Bh9uTPC8e8w4uN_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1MzY7aD04NjA-/https://media.zenfs.com/en/insidermonkey.com/c76d68c9002ff70d62300d60da1e4fbe","https://thumbor.evrimagaci.org/9_TewT2-pNBL6xGl_Cw2uKFDn2E=/1200x0/filters:quality(85):sharpen(0.5,0.5,true)/tpg%2Fsources%2Fb0b7e3ba-3685-4d22-ba99-6ca18f23c603.jpeg","https://s3.amazonaws.com/wp-uploads-trefis/articles/wp-content/uploads/2025/09/30062419/Daily-Winning-Streaks-300x200.png","https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","https://images.healthandme.com/thumb/msid-153466528,thumbsize-38466,width-1280,height-720,resizemode-3/153466528.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w630","https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg","https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2025/12/22012501/pexels-chokniti-khongchum-1197604-39380221.jpg","https://tokenist.com/wp-content/uploads/2026/01/73557919_m-2-646x360.jpg","https://oncodaily.com/pub/uploads/2026/01/IMG_9369.webp","https://s.yimg.com/os/en/insidermonkey.com/d26536c3fec5ce63e7d19890864ebe81","https://www.theglobeandmail.com/resizer/v2/C4LBZLYPWFDGPP43NG4TGZWTOE.jpg?auth=ab532960f16afe5907bfeebfba6a3d673239c7380402cdbe8b5c3ab13c13c518&width=300&height=300&quality=80&smart=true","https://s.yimg.com/ny/api/res/1.2/4GL0E9guD2s.39vrbMbfsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTI-/https://media.zenfs.com/en/us.finance.gurufocus/f59527b0d156b3bd2c9001300b62b795","https://content.timothysykes.com/cdn-cgi/image/quality=90,format=webp,width=740/https://content.timothysykes.com/wp-content/uploads/2026/01/immunitybios-stock-soars-spromising-drug-trials-and-revenue-growths.png","**Regulatory compliance represents a critical competitive moat in healthcare and biotechnology markets**, with ImmunityBio's ANKTIVA case study revealing strategic insights for cross-border sellers navigating complex approval processes.\n\n**The FDA's collaborative approach with ImmunityBio demonstrates how precise regulatory engagement can transform market opportunities.** The company's potential supplemental Biologics License Application (sBLA) resubmission in 2025 highlights a critical pathway for medical innovation. Key indicators include the 26% stock surge following regulatory discussions and the FDA's willingness to outline a resubmission path without demanding new clinical trials.\n\nFor cross-border sellers in healthcare and medical technology, this case underscores several strategic imperatives:\n\n1. **Regulatory Navigation as Competitive Advantage**: The ability to effectively communicate with regulatory bodies can dramatically reduce market entry barriers. ImmunityBio's 96% disease-specific survival data and 92% cystectomy avoidance metrics demonstrate how comprehensive clinical evidence supports regulatory discussions.\n\n2. **Global Market Access Strategy**: ANKTIVA's approvals across multiple regions (FDA, UK's MHRA, Saudi Arabia's SFDA) illustrate the importance of multi-market regulatory compliance. Sellers should view regulatory approval as a scalable, transferable asset that opens international market opportunities.\n\n3. **Compliance as Market Differentiation**: The treatment's unique IL-15 agonist immunotherapy approach represents how technical innovation combined with rigorous compliance can create significant market value. The 82% bladder preservation rate positions the product as a transformative medical solution.\n\nSellers can extract broader strategic lessons: precise documentation, proactive regulatory communication, and building comprehensive clinical evidence can turn compliance from a cost center into a competitive advantage. The biotech sector demonstrates how meticulous regulatory navigation can generate substantial market valuation and investor confidence.",[49,52,55,58],{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"What are the key indicators of successful regulatory navigation?","Successful regulatory navigation is indicated by stock performance, willingness of regulatory bodies to engage constructively, clear guidance on additional requirements, and the ability to expand product labels across multiple markets.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"What makes the FDA's approach to ImmunityBio significant for market entry?","The FDA's collaborative approach, offering a clear resubmission path without demanding new clinical trials, shows how constructive regulatory dialogue can accelerate market access. This approach reduces compliance costs and speeds up product introduction.",{"title":56,"answer":57,"author":5,"avatar":5,"time":5},"How can cross-border sellers apply biotech compliance lessons to other industries?","Sellers can adopt a proactive compliance approach by investing in comprehensive documentation, building strong relationships with regulatory bodies, and viewing compliance as a strategic asset rather than a bureaucratic burden.",{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"How can sellers use regulatory compliance as a competitive strategy?","Regulatory compliance can be a market differentiator by demonstrating technical expertise, reducing market entry barriers, and building trust with international regulators. Comprehensive documentation, proactive communication, and robust clinical evidence are key strategies.",[62,67,72,76,80,84,88,92,96,100,104,108,112,117,120,124,128,132,136,139,143,148,152,156,160,164,168,172,176,180,183,186,190,194,198,202,207,211,214,218,222,227,231,235,239,243,247,251,255],{"id":63,"title":64,"source":65,"logo":27,"time":66},269549,"This Biotech Stock Is Up More Than 100% This Year. Why It’s Soaring Again Today.","https://www.barrons.com/articles/biotech-stock-immunitybio-cancer-drug-84f69281?gaa_at=eafs&gaa_n=AWEtsqcLDDhQbrBHA0z1dKqQlp2GrKwEkwo6OET8BL3f2MvYsJ7LDkBCUSDn&gaa_ts=69705518&gaa_sig=oesBFMduj5py8_Dp99HpJwpHjyiyaFZ4rzs0lfQ4zt0dy28Ow_QzRMiyBKUgIXl6lqJl5QrfB0ZPqsFpTChfvA%3D%3D","6天前",{"id":68,"title":69,"source":70,"logo":5,"time":71},268459,"ImmunityBio soars 27% after FDA offers surprise lifeline","https://rollingout.com/2026/01/20/immunitybio-stock-jumps-27-percent-fda/","2天前",{"id":73,"title":74,"source":75,"logo":5,"time":66},269548,"ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits?","https://finance.yahoo.com/news/immunitybio-ibrx-extends-gains-10th-163303735.html",{"id":77,"title":78,"source":79,"logo":18,"time":71},268456,"ImmunityBio tries again in papillary bladder cancer | ApexOnco - Clinical Trials news and analysis","https://www.oncologypipeline.com/apexonco/immunitybio-tries-again-papillary-bladder-cancer",{"id":81,"title":82,"source":83,"logo":20,"time":71},269545,"ImmunityBio Extends Rally After FDA Talks","https://www.tradingview.com/news/gurufocus:260d552a7094b:0-immunitybio-extends-rally-after-fda-talks/",{"id":85,"title":86,"source":87,"logo":21,"time":71},268455,"ImmunityBio shares jump on Anktiva resubmission hopes","https://www.thepharmaletter.com/biotech-news/immunitybio-shares-jump-on-anktiva-resubmission-hopes",{"id":89,"title":90,"source":91,"logo":17,"time":71},268458,"ImmunityBio surge continues on sign its drug may be approved to treat a broader range of bladder cancers","https://sherwood.news/markets/immunitybio-surge-continues-on-sign-its-drug-may-be-approved-to-treat-a/",{"id":93,"title":94,"source":95,"logo":5,"time":66},269547,"ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year","https://www.biospace.com/press-releases/immunitybio-reports-continued-execution-and-sales-momentum-with-113-million-of-preliminary-net-product-revenue-a-700-increase-year-over-year",{"id":97,"title":98,"source":99,"logo":14,"time":71},268457,"Why Is ImmunityBio Stock Back In Retail Spotlight Today?","https://newsable.asianetnews.com/markets/why-is-immunitybio-stock-back-in-retail-spotlight-today-articleshow-se7ak8z",{"id":101,"title":98,"source":102,"logo":12,"time":103},269546,"https://stocktwits.com/news-articles/markets/equity/why-is-immunity-bio-stock-back-in-retail-spotlight-today/cmUu30MR49M","3天前",{"id":105,"title":106,"source":107,"logo":40,"time":103},268463,"ImmunityBio, Inc. (IBRX): A Bull Case Theory","https://finviz.com/news/280500/immunitybio-inc-ibrx-a-bull-case-theory",{"id":109,"title":110,"source":111,"logo":5,"time":71},268462,"ImmunityBio stock soars after FDA meeting on bladder cancer treatment","https://www.investing.com/news/stock-market-news/immunitybio-stock-soars-after-fda-meeting-on-bladder-cancer-treatment-93CH-4455289",{"id":113,"title":114,"source":115,"logo":11,"time":116},268465,"Saudi: SFDA approves registration of 'Anktiva' for treatment of bladder and lung cancer","https://www.zawya.com/en/business/healthcare/saudi-sfda-approves-registration-of-anktiva-for-treatment-of-bladder-and-lung-cancer-ar0373vn","4天前",{"id":118,"title":106,"source":119,"logo":32,"time":103},268464,"https://finance.yahoo.com/news/immunitybio-inc-ibrx-bull-case-222110563.html",{"id":121,"title":122,"source":123,"logo":41,"time":71},268461,"Why Are IBRX Shares Up in Premarket? FDA Feedback Boosts ANKTIVA","https://tokenist.com/why-are-ibrx-shares-up-in-premarket-fda-feedback-boosts-anktiva/",{"id":125,"title":126,"source":127,"logo":46,"time":71},268460,"ImmunityBio’s Stock Surges Amid Promising Drug Trials and Revenue Growth","https://www.timothysykes.com/news/immunitybio-inc-ibrx-news-2026_01_20/",{"id":129,"title":130,"source":131,"logo":28,"time":71},268449,"Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer","https://finance.yahoo.com/news/stock-market-today-jan-20-230714765.html",{"id":133,"title":134,"source":135,"logo":12,"time":71},268448,"This FDA Signal Is Powering IBRX Stock's Pre-Market Jump","https://stocktwits.com/news-articles/markets/equity/why-ibrx-stock-surging-premarket-fda-anktiva-resubmission/cmUujB3R4aL",{"id":137,"title":64,"source":138,"logo":27,"time":66},270326,"https://www.barrons.com/articles/biotech-stock-immunitybio-cancer-drug-84f69281?gaa_at=eafs&gaa_n=AWEtsqf5gknX8C84W5l37a7Slkh3ILjy94xgcrGE4skhPd8Htauo7umLAccI&gaa_ts=69708c52&gaa_sig=Gg-GOB79SrSnJ9pkc0wnXlcmaJgn1OFkxifxPnbYJgnp6WtE0oq1ZOqqaEBzoIe6KPTU3P3WeVmyUxq0arpTuA%3D%3D",{"id":140,"title":141,"source":142,"logo":25,"time":66},270325,"Nogapendekin Alfa Inbakicept Plus BCG Yields Significant DOR in BCG-Naive NMIBC","https://www.onclive.com/view/nogapendekin-alfa-inbakicept-plus-bcg-yields-significant-dor-in-bcg-naive-nmibc",{"id":144,"title":145,"source":146,"logo":29,"time":147},270324,"ImmunityBio Stock (IBRX) Keeps Flying as FDA Update Fuels Momentum","https://www.tipranks.com/news/immunitybio-stock-ibrx-keeps-flying-as-fda-update-fuels-momentum","1天前",{"id":149,"title":150,"source":151,"logo":38,"time":71},268447,"ImmunityBio extends gains after FDA views on Anktiva label expansion","https://seekingalpha.com/news/4540338-immunitybio-gets-fda-views-anktiva-label-expansion",{"id":153,"title":154,"source":155,"logo":26,"time":147},270323,"IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing","https://newsable.asianetnews.com/markets/ibrx-stock-extends-rally-on-fda-feedback-for-anktiva-bladder-cancer-filing-articleshow-7gmhtiy",{"id":157,"title":158,"source":159,"logo":36,"time":147},270322,"ImmunityBio Approval And Trial Updates Spark Valuation Debate For Investors","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-approval-and-trial-updates-spark-valuation-debat",{"id":161,"title":162,"source":163,"logo":35,"time":147},270321,"IBRX Stock Surges 227% With A 12-day Winning Spree On 700% Revenue Growth","https://www.trefis.com/data/companies/IBRX/no-login-required/40C2oyny/IBRX-Stock-Surges-227-With-A-12-day-Winning-Spree-On-700-Revenue-Growth",{"id":165,"title":166,"source":167,"logo":43,"time":147},270320,"ImmunityBio (IBRX) Rockets on 12th Day, Hits Fresh High","https://finance.yahoo.com/news/immunitybio-ibrx-rockets-12th-day-072815679.html",{"id":169,"title":170,"source":171,"logo":5,"time":71},268452,"Bladder cancer drug ANKTIVA shows 96% survival as FDA reviews new data","https://www.stocktitan.net/news/IBRX/immunity-bio-advances-regulatory-discussions-with-fda-on-potential-ak8bfcexfh8f.html",{"id":173,"title":174,"source":175,"logo":5,"time":71},268451,"ImmunityBio Advances ANKTIVA Application with FDA Meeting, Achieving 96% Survival Rate at 36 Months","https://intellectia.ai/news/stock/immunitybio-advances-anktiva-application-with-fda-meeting-achieving-96-survival-rate-at-36-months",{"id":177,"title":178,"source":179,"logo":19,"time":71},268454,"Supplemental Information Requested For Nogapendekin Alfa sBLA in NMIBC Type","https://www.cancernetwork.com/view/supplemental-information-requested-for-nogapendekin-alfa-sbla-in-nmibc-type",{"id":181,"title":82,"source":182,"logo":45,"time":71},268453,"https://finance.yahoo.com/news/immunitybio-extends-rally-fda-talks-181935819.html",{"id":184,"title":130,"source":185,"logo":30,"time":71},268450,"https://www.fool.com/coverage/stock-market-today/2026/01/20/stock-market-today-jan-20-immunitybio-soars-again-after-fda-outlines-resubmission-path-for-anktiva-in-bladder-cancer/",{"id":187,"title":188,"source":189,"logo":33,"time":103},268679,"ImmunityBio (IBRX) Soars 137% on Expansion Plan, Clinical Results","https://finance.yahoo.com/news/immunitybio-ibrx-soars-137-expansion-021559375.html",{"id":191,"title":192,"source":193,"logo":5,"time":66},268478,"ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG","https://investingnews.com/immunitybio-advances-first-line-bcg-naive-nmibc-program-with-enrollment-exceeding-expectations-and-positive-interim-analysis-for-anktiva-r-plus-bcg/",{"id":195,"title":196,"source":197,"logo":23,"time":66},268477,"Saudi FDA Approves Anktiva for Bladder and Lung Cancer","https://oncodaily.com/oncolibrary/anktiva",{"id":199,"title":200,"source":201,"logo":39,"time":71},268678,"ImmunityBio Stock Surges 26% After FDA Outlines Resubmission Path For ANKTIVA","https://www.nasdaq.com/articles/immunitybio-stock-surges-26-after-fda-outlines-resubmission-path-anktiva",{"id":203,"title":204,"source":205,"logo":44,"time":206},268479,"Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%","https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/37072197/stock-market-today-jan-15-immunitybio-surges-after-anktiva-revenue-jumps-700/","7天前",{"id":208,"title":209,"source":210,"logo":5,"time":71},268677,"ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA","https://www.businesswire.com/news/home/20260120371998/en/ImmunityBio-Advances-Regulatory-Discussions-with-FDA-on-Potential-Resubmission-Path-for-ANKTIVA-in-BCG-Unresponsive-Papillary-Bladder-Cancer",{"id":212,"title":166,"source":213,"logo":22,"time":147},270319,"https://www.insidermonkey.com/blog/immunitybio-ibrx-rockets-on-12th-day-hits-fresh-high-1678654/",{"id":215,"title":216,"source":217,"logo":5,"time":103},268467,"Study progresses of nogapendekin alfa inbakicept for BCG-naïve NMIBC","https://www.urologytimes.com/view/study-progresses-of-nogapendekin-alfa-inbakicept-for-bcg-na-ve-nmibc",{"id":219,"title":220,"source":221,"logo":10,"time":103},268466,"Why ImmunityBio’s Surging Stock Faces a Sharp Reversal","https://www.tipranks.com/news/catalyst/why-immunitybios-surging-stock-faces-a-sharp-reversal",{"id":223,"title":224,"source":225,"logo":34,"time":226},268469,"ImmunityBio Shares Soar On 700 Percent Revenue Surge","https://evrimagaci.org/gpt/immunitybio-shares-soar-on-700-percent-revenue-surge-524308","5天前",{"id":228,"title":229,"source":230,"logo":42,"time":103},268468,"Pat Soon-Shiong: Anktiva as a New Treatment Option for Patients with Limited Therapeutic Alternatives","https://oncodaily.com/voices/pat-soon-shiong-443413",{"id":232,"title":233,"source":234,"logo":31,"time":66},268474,"ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) (NASDAQ:IBRX)","https://seekingalpha.com/article/4860611-mmunitybio-making-strides-but-beware-the-hype-rating-downgrade",{"id":236,"title":237,"source":238,"logo":35,"time":226},268473,"IBRX Stock Surges 179% With A 11-day Winning Spree On 700% Revenue Growth","https://www.trefis.com/data/companies/IBRX/no-login-required/nSeXb4PV/IBRX-Stock-Surges-179-With-A-11-day-Winning-Spree-On-700-Revenue-Growth",{"id":240,"title":241,"source":242,"logo":16,"time":66},268476,"Why ImmunityBio Stock Is Skyrocketing Again Today","https://www.fool.com/investing/2026/01/16/why-immunitybio-stock-is-skyrocketing-again-today/",{"id":244,"title":245,"source":246,"logo":15,"time":66},268475,"Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year","https://finance.yahoo.com/news/stock-market-today-jan-16-221723620.html",{"id":248,"title":249,"source":250,"logo":24,"time":116},268470,"Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline","https://ts2.tech/en/why-immunitybio-stock-jumped-nearly-40-anktiva-sales-surge-and-a-fresh-trial-timeline/",{"id":252,"title":253,"source":254,"logo":13,"time":226},268472,"Saudi Arabia Records Treatment for Bladder and Lung Cancer Patients","https://www.sadanews.ps/en/news/267212.html",{"id":256,"title":257,"source":258,"logo":37,"time":116},268471,"Anktiva Approved In Saudi Arabia As World’s First Lung Cancer Therapy — All You Need to Know","https://www.healthandme.com/health-news/anktiva-approved-in-saudi-arabia-as-worlds-first-lung-cancer-therapy-all-you-need-to-know-article-153466528","#5d0c93ff","#5d0c934d",1769160703836]